Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib

[1]  M. Bolognesi,et al.  Structural basis for bivalent Smac-mimetics recognition in the IAP protein family. , 2009, Journal of molecular biology.

[2]  M. Bolognesi,et al.  Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy. , 2009, Bioorganic & medicinal chemistry.

[3]  A. Strongin,et al.  Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells , 2009, Molecular Cancer Therapeutics.

[4]  U. Bhanot,et al.  Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. , 2009, Cancer research.

[5]  H. Walczak,et al.  Is TRAIL the holy grail of cancer therapy? , 2009, Apoptosis.

[6]  Stephen J. Morris,et al.  Cytoprotective effects of IAPs revealed by a small molecule antagonist. , 2009, The Biochemical journal.

[7]  M. Bolognesi,et al.  Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. , 2009, Biochemical and biophysical research communications.

[8]  Carlo Scolastico,et al.  Targeting the X-linked inhibitor of apoptosis protein through 4-substituted azabicyclo[5.3.0]alkane smac mimetics. Structure, activity, and recognition principles. , 2008, Journal of molecular biology.

[9]  Shaomeng Wang,et al.  SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. , 2008, Cancer research.

[10]  S. Fulda,et al.  Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. , 2008, Cancer research.

[11]  M. Bertrand,et al.  cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. , 2008, Molecular cell.

[12]  R. Herbst,et al.  To kill a tumor cell: the potential of proapoptotic receptor agonists. , 2008, The Journal of clinical investigation.

[13]  Xiaodong Wang,et al.  TNF-α Induces Two Distinct Caspase-8 Activation Pathways , 2008, Cell.

[14]  M. Todaro,et al.  Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4 , 2008, Cell Death and Differentiation.

[15]  Shaomeng Wang,et al.  Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. , 2008, Analytical biochemistry.

[16]  J. Magae,et al.  Bid truncation mediated by caspases-3 and -9 in vinorelbine-induced apoptosis , 2008, Apoptosis.

[17]  P. Hersey,et al.  Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein. , 2008, Cancer research.

[18]  W. Sellers,et al.  A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. , 2007, Cancer research.

[19]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[20]  Vishva M. Dixit,et al.  IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.

[21]  J. Minna,et al.  Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. , 2007, Cancer cell.

[22]  P. Hersey,et al.  Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response. , 2007, Carcinogenesis.

[23]  Nizar M. Mhaidat,et al.  Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. , 2007, Cancer research.

[24]  J. Meixensberger,et al.  Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis , 2007, Clinical Cancer Research.

[25]  J. Eberle,et al.  Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-κB but is related to downregulation of initiator caspases and DR4 , 2007, Oncogene.

[26]  M. Krönke,et al.  NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. , 2007, Blood.

[27]  J. Köllermann,et al.  Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance. , 2007, International journal of cancer.

[28]  J. Köllermann,et al.  Expression parameters of the inhibitors of apoptosis cIAP1 and cIAP2 in renal cell carcinomas and their prognostic relevance , 2006 .

[29]  Shaomeng Wang,et al.  Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. , 2006, Journal of medicinal chemistry.

[30]  Andreas Untergasser,et al.  Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs , 2006, Clinical Cancer Research.

[31]  G. Salvesen,et al.  The Human Anti-apoptotic Proteins cIAP1 and cIAP2 Bind but Do Not Inhibit Caspases* , 2006, Journal of Biological Chemistry.

[32]  Ralf Bartenschlager,et al.  E2 of Hepatitis C Virus Inhibits Apoptosis1 , 2005, The Journal of Immunology.

[33]  J. Eberle,et al.  Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). , 2005, The Journal of investigative dermatology.

[34]  N. Munshi,et al.  Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). , 2004, Blood.

[35]  Xueliang Fang,et al.  Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. , 2004, Analytical biochemistry.

[36]  Xiaodong Wang,et al.  A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death , 2004, Science.

[37]  Saul H Rosenberg,et al.  Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. , 2004, Journal of medicinal chemistry.

[38]  W. Stremmel,et al.  Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs , 2004, Cell Death and Differentiation.

[39]  K. Kinzler,et al.  X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. , 2004, Cancer research.

[40]  P. Hersey,et al.  Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. , 2001, Cancer research.

[41]  Geng Wu,et al.  Structural basis of IAP recognition by Smac/DIABLO , 2000, Nature.

[42]  Stephen F. Betz,et al.  Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain , 2000, Nature.

[43]  Xiaodong Wang,et al.  Smac, a Mitochondrial Protein that Promotes Cytochrome c–Dependent Caspase Activation by Eliminating IAP Inhibition , 2000, Cell.

[44]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[45]  C. Rüegg,et al.  Clinical applications of TNF-α in cancer , 1998 .

[46]  J C Reed,et al.  IAPs block apoptotic events induced by caspase‐8 and cytochrome c by direct inhibition of distinct caspases , 1998, The EMBO journal.

[47]  J C Reed,et al.  A Single BIR Domain of XIAP Sufficient for Inhibiting Caspases* , 1998, The Journal of Biological Chemistry.

[48]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[49]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[50]  A. Chadli.  THE CANCER CELL , 1924, La Presse medicale.

[51]  G. Morgan,et al.  Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy , 2005, Cancer Cell International.

[52]  R. Bartenschlager,et al.  E2 of Hepatitis C Virus Inhibits Apoptosis , 2005 .

[53]  Xiaodong Wang,et al.  A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. , 2004, Science.

[54]  K. Schulze-Osthoff,et al.  Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. , 2001, Blood.